Skip to main content
Treatment of Multiple Myeloma and Related Disorders
  • Export citation
  • Recommend to librarian
  • Recommend this book

    Email your librarian or administrator to recommend adding this book to your organisation's collection.

    Treatment of Multiple Myeloma and Related Disorders
    • Online ISBN: 9780511551901
    • Book DOI:
    Please enter your name
    Please enter a valid email address
    Who would you like to send this to? *
  • Buy the print book

Book description

Due to major advances in understanding the biology and pathogenesis of the disease, the management of multiple myeloma is changing rapidly. New diagnostic and prognostic criteria have been introduced, and treatment options are multiplying with high-dose chemotherapy regimens, stem cell transplants, and the development of novel agents and immune-based strategies that target tumor cells directly. This book is aimed at the practitioner who is looking to put these advances into clinical context. It will serve as an up-to-date resource for treatment of myeloma and related disorders. Chapters are written by international authorities and contain color photos, diagrams, and algorithms outlining preferred treatment strategies. Relevant scientific information is integrated throughout, but the focus here is on providing practical therapeutic guidance for oncologists and hematologists caring for myeloma patients. The book covers all myeloma subtypes and related disorders, including amyloidosis, Waldenstrom macroglobulinemia, plasmacytoma, MGUS, and POEMS syndrome.


    • Aa
    • Aa
Refine List
Actions for selected content:
Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Send to Kindle
  • Send to Dropbox
  • Send to Google Drive
  • Send content to

    To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to .

    To send content to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

    Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

    Find out more about the Kindle Personal Document Service.

    Please be advised that item(s) you selected are not available.
    You are about to send:

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

R Fonseca , B Barlogie , R Bataille , et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64(4):1546–58.

NV Smadja , C Fruchart , F Isnard , et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 1998;12(6):960–9.

C Debes-Marun , G Dewald , S Bryant , et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003;17(2):427–36.

R Fonseca , CS Debes-Marun , EB Picken , et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003;102(7):2562–7.

NV Smadja , D Leroux , J Soulier , et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 2003;38(3):234–9.

P Noel , RA. Kyle Plasma cell leukemia: an evaluation of response to therapy. Am J Med 1987;83(6):1062–8.

WJ Chng , RP Ketterling , R. Fonseca Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. Genes Chromosomes Cancer 2006;45(12):1111–20.

WJ Chng , S Kumar , S Vanwier , et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007;67(7):2982–9.

PR Greipp , MC Trendle , T Leong , et al. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma 1999;35(1–2):83–9.

WJ Chng , JM Winkler , PR Greipp , et al. Ploidy status rarely changes in myeloma patients at disease progression. Leuk Res 2006;30(3):266–71.

YL Kwong , AK Lie , LC. Chan Translocation (11;14)(q13;q32) and partial trisomy 1q in a case of multiple myeloma [letter]. Am J Hematol 1993;44(3):212–13.

JR Sawyer , JA Waldron , S Jagannath , B. Barlogie Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995;82(1):41–9.

R Fonseca , TE Witzig , MA Gertz , et al. Multiple myeloma and the translocation t(11;14)(q13;q32) – a report on 13 cases. Br J Haematol 1998;101(2):296–301.

PL Bergsagel , M Chesi , E Nardini , Brents LA, SL Kirby , WM. Kuehl Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996;93(24):13931–6.

M Chesi , E Nardini , Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genet 1997;16(3):260–4.

H Avet-Loiseau , M Attal , P Moreau , et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109(8):3489–95.

R Fonseca , D Harrington , M Oken , et al. Myeloma and the t(11;14)(q13;q32) represents a uniquely defined biological subset of patients. Blood 2002;99(10):3735–41.

JR Sawyer , JL Lukacs , EL Thomas , et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol 2001;112(1):167–74.

R Garand , H Avet-Loiseau , F Accard , P Moreau , J Harousseau , R. Bataille t(11;14) and t(4;14) translocations correlated with mature lymphoplasmocytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003;this issue.

F Zhan , Y Huang , S Colla , et al. The molecular classification of multiple myeloma. Blood 2006;108(6):2020–8.

J Shaughnessy Jr., A Gabrea , Y Qi , et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001;98(1):217–23.

JJ Keats , T Reiman , CA Maxwell , et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003;101(4):1520–9.

JP Stewart , A Thompson , M Santra , B Barlogie , TR Lappin , J Shaughnessy Jr. Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma. Br J Haematol 2004;126(1):72–6.

R Fonseca , E Blood , M Rue , et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101(11):4569–75.

H Chang , S Sloan , D Li , et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004;125(1):64–8.

H Chang , XY Qi , S Samiee , et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant 2005;36(9):793–6.

MV Mateos , JM Hernandez , MT Hernandez , et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood 2006;108(7):2165–72.

S Trudel , S Ely , Y Farooqi , et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 2004;103(9):3521–8.

S Trudel , ZH Li , E Wei , et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005;105(7):2941–8.

H Avet-Loiseau , T Facon , B Grosbois , et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002;99(6):2185–91.

R Fonseca , MM Oken , PR. Greipp The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 2001;98(4):1271–2.

JD Shaughnessy Jr., F Zhan , BE Burington , et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109(6):2276–84.

PL Bergsagel , WM. Kuehl Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 2003;194:96–104.

JD Shaughnessy Jr. Global gene expression profiling in the study of multiple myeloma. [Review] [94 refs]. Int J Hematol 2003;77(3):213–25.

DR Carrasco , G Tonon , Y Huang , et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006;9(4):313–25.

H Avet-Loiseau , A Daviet , S Saunier , R. Bataille Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 2000;111(4):1116–7.

R Fonseca , M Oken , D Harrington , et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q-arm or monosomy. Leukemia 2001;15:981–6.

R Konigsberg , J Ackermann , H Kaufmann , et al. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia 2000;14(11):1975–9.

BA Walker , PE Leone , MW Jenner , et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 2006;108(5):1733–43.

MO Elnenaei , RA Hamoudi , J Swansbury , et al. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer 2003;36(1):99–106.

S Bezieau , MC Devilder , H Avet-Loiseau , et al. High incidence of N- and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001;18(3):212–24.

A Neri , JP Murphy , L Cro , et al. Ras oncogene mutation in multiple myeloma. J Exp Med 1989;170(5):1715–25.

T Rasmussen , M Kuehl , M Lodahl , HE Johnsen , IM. Dahl Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition some plasma cell tumors. Blood 2005;105(1):317–23.

H Chang , S Sloan , D Li , A. Keith Stewart Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004;127(3):280–4.

H Chang , C Qi , QL Yi , D Reece , AK. Stewart p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005;105(1):358–60.

WJ Chng , T Price-Troska , N Gonzalez-Paz , et al. Clinical significance of TP53 mutation in myeloma. Leukemia 2007;21(3):582–4.

RE Tiedemann , N Gonzalez-Paz , RA Kyle , et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008;22(5):1044–52.

PG. Richardson A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother 2004;5(6):1321–31.

G Mulligan , C Mitsiades , B Bryant , et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109(8):3177–88.

H Avet-Loiseau , F Gerson , F Magrangeas , S Minvielle , JL Harousseau , R. Bataille Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001;98(10):3082–6.

WM Kuehl , PL. Bergsagel Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2(3):175–87.

Y Shou , ML Martelli , A Gabrea , et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 2000;97(1):228–33.

H Avet-Loiseau , A Daviet , C Brigaudeau , et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 2001;97(3):822–5.

M Chesi , DF Robbiani , M Sebag , et al. AID-dependent MYC activation induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008;(in press).

H Chang , X Qi , Y Trieu , et al. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol 2006;135(4):486–91.

R Fonseca , SA Wier Van, WJ Chng , et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006;20(11):2034–40.

I Hanamura , JP Stewart , Y Huang , et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem cell transplantation. Blood 2006;108(5):1724–32.

F Zhan , S Colla , X Wu , et al. CKS1B, over expressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and independent mechanisms. Blood 2007;109(11):4995–5001.

KL Wu , B Beverloo , HM Lokhorst , et al. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol 2007;136(4):615–23.

H Chang , Y Ning , X Qi , J Yeung , W. Xu Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Br J Haematol 2007;139(1):51–4.

MV Mateos , R Garcia-Sanz , R Lopez-Perez , et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002;118(4):1034–40.

C Ribas , GW Colleoni , RS Felix , et al. p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma. Cancer Lett 2005;222(2):247–54.

A Dib , B Barlogie , JD Shaughnessy Jr., WM. Kuehl Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood 2007;109(3):1337–8.

N Gonzalez-Paz , WJ Chng , RF Mcclure , et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007;109(3):1228–32.

T Tasaka , J Berenson , R Vescio , et al. Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma. Br J Haematol 1997;96(1):98–102.

HG. Drexler Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998;12(6):845–59.

MS Kulkarni , JL Daggett , TP Bender , WM Kuehl , PL Bergsagel , ME. Williams Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia 2002;16(1):127–34.

WJ Chng , WM Kuehl , PL Bergsagel , R. Fonseca Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia 2008;22(2):459–61.

WJ Chng , GJ Ahmann , K Henderson , et al. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood 2006;107(9):3669–75.

AK Stewart , PL Bergsagel , PR Greipp , et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007;21(3):529–34.

H Avet-Loiseau , A Daviet , C Brigaudeau , et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 2001;97(3):822–5.

SR Hayman , RJ Bailey , SM Jalal , et al. Translocations involving heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood 2001;98:2266–8.

CJ Harrison , H Mazzullo , FM Ross , et al. Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol 2002;117(2):427–35.

MA Gertz , MQ Lacy , A. Dispenzieri Amyloidosis: Recognition, confirmation, prognosis, and therapy [Review]. Mayo Clin Proc 1999;74(5):490–4.

H Avet-Loiseau , R Garand , L Lode , JL Harousseau , R. Bataille Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 2003;101(4):1570–1.

RF Schop , WM Kuehl , SA Wier Van, et al. Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002;100(8):2996–3001.

NV Smadja , C Bastard , C Brigaudeau , D Leroux , C. Fruchart Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001;98(7):2229–38.

SV Rajkumar , R Fonseca , GW Dewald , et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999;113(1):73–7.

PR Greipp , J San Miguel , BG Durie , et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412–20.

JF San Miguel , R. Garcia-Sanz Prognostic features of multiple myeloma. Best Pract Res Clin Haematol 2005;18:569–83.

PL Bergsagel , WM. Kuehl Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333–8.

SV Rajkumar , R Fonseca , MQ Lacy , et al. Beta-2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant 1999;23:1261–6.

PL Bergsagel , WM Kuehl , F Zhan , J Sawyer , B Barlogie , J Shaughnessy Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106: 296–303.

WJ Chng , R Santana-Davila , SA Wier Van, et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 2006;20:807–13.

WJ Chng , SA Wier Van, GJ Ahmann , et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 2005;106:2156–61.

R Fonseca , GJ Ahmann , SM Jalal , et al. Chromosomal abnormalities in systemic amyloidosis. Br J Haematol 1998;103:704–10.

PL Bergsagel , WM. Kuehl Chromosome translocations in multiple myeloma. Oncogene 2001;20:5611–22.

AK Stewart , H Chang , S Trudel , et al. Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Leukemia 2007;21:2358–9.

MA Gertz , MQ Lacy , A Dispenzieri , et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837–40.

W Jaksic , S Trudel , H Chang , et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005;23:7069–73.

A Dispenzieri , SV Rajkumar , MA Gertz , et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007;82:323–41.

JJ Keats , R Fonseca , M Chesi , et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131–44.

J. Shaughnessy Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 2005;10(suppl 1):117–26.

B Barlogie , JD Shaughnessy Jr. Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH. Int J Hematol 2002;76(suppl 1):337–9.

F Zhan , B Barlogie , G Mulligan , JR Shaughnessy Jd , B. Bryant High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood 2008;111:968–9.

H Chang , Y Trieu , X Qi , W Xu , KA Stewart , D. Reece Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2006; 31:779–82.

RA Kyle , SV. Rajkumar Multiple myeloma. N Engl J Med 2004;351:1860–73.

SV Rajkumar , RA. Kyle Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005;80:1371–82.

RA Kyle , SV. Rajkumar Multiple myeloma. Blood 2008;111:2962–72.

M Attal , JL Harousseau , AM Stoppa , et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–7.

SV Rajkumar , SR Hayman , MQ Lacy , et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050–3.

PG Richardson , E Blood , CS Mitsiades , et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458–64.

SK Kumar , SV Rajkumar , A Dispenzieri , et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2007;111:2516–20.

M Hjorth , L Hellquist , E Holmberg , B Magnusson , S Rodjer , J. Westin Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I – a randomized study. Myeloma Group of Western Sweden. Eur J Haematol 1993;50:95–102.

G Grignani , PG Gobbi , R Formisano , et al. A prognostic index for multiple myeloma. Br J Cancer 1996;73:1101–7.

A Dispenzieri , SV Rajkumar , MA Gertz , et al. Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus Statement. Mayo Clin Proc 2007;82:323–41.

M Attal , JL Harousseau , T Facon , et al. Single versus double autologous stem-cell transplantation for multiple myeloma [see comment]. N Engl J Med 2003;349:2495–502.

B Bruno , M Rotta , F Patriarca , et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110–20.

SV. Rajkumar The death of VAD as initial therapy for multiple myeloma. Blood 2005;106:2–3.

SV Rajkumar , E Blood , DH Vesole , R Fonseca , PR. Greipp Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431–6.

SV Rajkumar , L RosiñOl , M Hussein , et al. A multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone versus dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26: 2171–7.

T Facon , J-Y Mary , B Pegourie , et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006;107:1292–8.

SV Rajkumar , S Hayman , MA Gertz , et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319–23.

S Kumar , A Dispenzieri , MQ Lacy , et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post- peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007;21:2035–42.

R Niesvizky , DS Jayabalan , PJ Christos , et al. BiRD (Biaxin(R)[clarithromycin]/Revlimid(R)[lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2007;111:1101–9.

S Jagannath , BG Durie , J Wolf , et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776–83.

A Palumbo , P Falco , P Corradini , et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459–65.

V Sagaster , H Ludwig , H Kaufmann , et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2006;21:164–8.

SV. Rajkumar Thalidomide therapy and deep venous thrombosis in multiple myeloma [comment]. Mayo Clin Proc 2005;80:1549–51.

R Alexanian , S Salmon , J Bonnet , E Gehan , A Haut , J. Weick Combination therapy for multiple myeloma. Cancer 1977;40(6):2765–71.

R Alexanian , R. Dreicer Chemotherapy for multiple myeloma. Cancer 1984;53(3):583–8.

IC Maclennan , J. Cusick Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults. Br J Cancer 1985;52(2):153–8.

A Belch , Bergsagel DShelley W, , et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988;57(1):94–9.

Myeloma Trialists’ Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001;113(4):1020–34.

E Fritz , H. Ludwig Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000;11(11):1427–36.

JR Berenson , JJ Crowley , TM Grogan , et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002;99(9):3163–8.

C Shustik , A Belch , S Robinson , et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 2007;136(2):203–11.

R Alexanian , D Weber , S Giralt , K. Delasalle Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 2002;13(7):1116–19.

AK Stewart , CI Chen , K Howson-Jan , et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004;10(24):8170–6.

S Feyler , A Rawstron , G Jackson , JA Snowden , K Cocks , RJ. Johnson Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Br J Haematol 2007;139(3):429–33.

M Attal , JL Harousseau , S Leyvraz , et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108(10):3289–94.

A Abdelkefi , S Ladeb , L Torjman , et al. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2007;111:1805–10.

KC Anderson , RA Kyle , SV Rajkumar , AK Stewart , D Weber , P. Richardson Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008;22(2):231–9.

R Alexanian , B Barlogie , D. Dixon High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986;105(1):8–11.

B Barlogie , Alexanian R.Smith L, Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310(21):1353–6.

H Anderson , JH Scarffe , M Ranson , et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995;71(2):326–30.

HM Lokhorst , OJ Meuwissen , EJ Bast , AW. Dekker VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989;71(1):25–30.

FJ Giles , NR Wickham , BL Rapoport , et al. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol. Am J Hematol 2000;63(3):125–30.

CK Lee , B Barlogie , N Munshi , et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21(14):2732–9.

IC Maclennan , C Chapman , J Dunn , K. Kelly Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet 1992;339(8787):200–5.

JR Berenson , HH Yang , K Sadler , et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006;24(6):937–44.

RZ Orlowski , PM Voorhees , RA Garcia , et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005;105(8):3058–65.

RZ Orlowski , A Nagler , P Sonneveld , et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25(25):3892–901.

S Kumar , MQ Lacy , A Dispenzieri , et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004;34(2):161–7.

CK Lee , B Barlogie , M Zangari , et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant 2002;30(12):873–8.

P Corradini , M Cavo , H Lokhorst , et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003;102(5):1927–9.

N Kroger , JA Perez-Simon , H Myint , et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004; 10(10):698–708.

GE Georges , MB Maris , DG Maloney , et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 2007; 13(4):423–2.

RJ D'Amato , MS Loughnan , E Flynn , J. Folkman Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91(9):4082–5.

A Vacca , D Ribatti , L Roncali , et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87(3):503–8.

KC. Anderson Lenalidomide and thalidomide: mechanisms of action – similarities and differences. Semin Hematol 2005;42 (4 suppl 4):S3-S8.

N Mitsiades , CS Mitsiades , V Poulaki , et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99(12):4525–30.

B Barlogie , R Desikan , P Eddlemon , et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98(2):492–4.

PG Richardson , C Mitsiades , R Schlossman , N Munshi , K. Anderson New drugs for myeloma. Oncologist 2007;12(6):664–89.

A Glasmacher , C Hahn , F Hoffmann , et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006;132(5):584–93.

SA Schey , J Cavenagh , R Johnson , JA Child , H Oakervee , RW. Jones An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 2003;27(10):909–14.

P Richardson , R Schlossman , S Jagannath , et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004;79(7):875–82.

L Mileshkin , R Stark , B Day , JF Seymour , JB Zeldis , HM. Prince Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24(27):4507–14.

D Weber , K Rankin , M Gavino , K Delasalle , R. Alexanian Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21(1):16–19.

R Alexanian , D Weber , A Anagnostopoulos , K Delasalle , M Wang , K. Rankin Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 2003;40(4 suppl 4):3–7.

MA Dimopoulos , K Zervas , G Kouvatseas , et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001;12(7):991–5.

A Palumbo , P Falco , MT Ambrosini , et al. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. Eur J Haematol 2005;75(5):391–5.

A Palumbo , A Bertola , P Falco , et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004;5(4):318–24.

A Palumbo , SV Rajkumar , MA Dimopoulos , et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414–23.

TM Moehler , K Neben , A Benner , et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001;98(13):3846–8.

MA Dimopoulos , G Hamilos , A Zomas , et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004;5(2):112–17.

C Kyriakou , K Thomson , S D'Sa , et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005;129(6):763–70.

JB Bartlett , K Dredge , AG. Dalgleish The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4(4):314–22.

PG Richardson , RL Schlossman , E Weller , et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100(9):3063–7.

DM Weber , C Chen , R Niesvizky , et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357(21):2133–42.

M Dimopoulos , A Spencer , M Attal , et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357(21):2123–32.

R Baz , E Walker , MA Karam , et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006;17(12):1766–71.

GJ Morgan , SA Schey , P Wu , et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007;137(3):268–9.

T Hideshima , KC. Anderson Preclinical studies of novel targeted therapies. Hematol Oncol Clin North Am 2007;21(6):1071–91.

PG Richardson , B Barlogie , J Berenson , et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348(26):2609–17.

S Jagannath , B Barlogie , J Berenson , et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127(2):165–72.

PG Richardson , H Briemberg , S Jagannath , et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24(19):3113–20.

S Lonial , EK Waller , PG Richardson , et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005;106(12):3777–84.

N Mitsiades , CS Mitsiades , PG Richardson , et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101(6):2377–80.

FE Davies , P Wu , M Jenner , M Srikanth , R Saso , GJ. Morgan The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 2007;92(8):1149–50.

M Kropff , G Bisping , E Schuck , et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007;138(3):330–7.

CS Mitsiades , NS Mitsiades , CJ Mcmullan , et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006; 107(3):1092–100.

N Mitsiades , CS Mitsiades , V Poulaki , et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002;99(22):14374–9.

T Hideshima , L Catley , H Yasui , et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107(10):4053–62.

R Garcia-Mata , YS Gao , E. Sztul Hassles with taking out the garbage: aggravating aggresomes. Traffic 2002;3(6):388–96.

Y Kawaguchi , JJ Kovacs , A Mclaurin , JM Vance , A Ito , TP. Yao The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115(6):727–38.

T Hideshima , JE Bradner , J Wong , et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005;102(24):8567–72.

CS Mitsiades , NS Mitsiades , CJ Mcmullan , et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004;101(2):540–5.

T Hideshima , M Akiyama , T Hayashi , et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003;101(2):703–5.

D Chauhan , M Velankar , M Brahmandam , et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007;26(16):2374–80.

D Chauhan , P Neri , M Velankar , et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007;109(3):1220–7.

K Podar , MS Raab , J Zhang , et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007;109(4):1669–77.

D Chauhan , A Singh , M Brahmandam , et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008;111(3):1654–64.

PG Richardson , P Sonneveld , MW Schuster , et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007;137(5): 429–35.

P Tosi , E Zamagni , C Cellini , et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004;73(2):98–103.

N Chen , H Lau , L Kong , et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007;47(12):1466–75.

Metzlervon, H Krebbel , M Hecht , et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007;21(9):2025–34.

GD. Roodman Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004;32:290–2.

LJ III Melton , RA Kyle , SJ Achenbach , AL Oberg , SV. Rajkumar Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 2005;20:487–93.

T Taube , MN Beneton , EV Mccloskey , S Rogers , M Greaves , JA. Kanis Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992;49:192–8.

F Saad , A Lipton , R Cook , YM Chen , M Smith , R. Coleman Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860–7.

KL Schulman , J. Kohles Economic burden of metastatic bone disease in the U.S. Cancer 2007;109:2334–42.

RA Kyle , TM Therneau , SV Rajkumar , DR Larson , MF Plevak , LJ Melton III. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer 2004; 101:2667–74.

BO. Oyajobi Multiple myeloma/hypercalcemia [review]. Arthritis Res Ther 2007;9 (suppl 1):S4.

C Sourbier , T. Massfelder Parathyroid hormone-related protein in human renal cell carcinoma. Cancer Lett 2006;240:170–82.

T Horiuchi , T Miyachi , T Arai , T Nakamura , M Mori , H. Ito Raised plasma concentrations of parathyroid hormone related peptide in hypercalcemic multiple myeloma. Horm Metab Res 1997;29:469–71.

K Wang , L Allen , E Fung , CC Chan , JC Chan , JF. Griffith Bone scintigraphy in common tumors with osteolytic components [review]. Clin Nucl Med 2005;30:655–71.

A Mele , M Offidani , G Visani , et al. Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans. Br J Haematol 2007;136:729–35.

FE Lecouvet , BC Vande Berg , J Malghem , BE. Maldague Magnetic resonance and computed tomography imaging in multiple myeloma. Semin Musculoskelet Radiol 2001;5:43–55.

S D'Sa , N Abildgaard , J Tighe , P Shaw , M. Hall-Craggs Guidelines for the use of imaging in the management of myeloma. Br J Haematol 2007;137:49–63.

FE Lecouvet , BC Vande Berg , L Michaux , et al. Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging. Radiology 1998;209:653–60.

R Walker , B Barlogie , J. Haessler Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007;25:1121–8.

MA Dimopoulos , Moulopoulos LA, I Datseris , et al. Imaging of myeloma bone disease – implications for staging, prognosis and follow-up. Acta Oncol 2000;39:823–7.

MA Bredella , L Steinbach , G Caputo , G Segall , R. Hawkins Value of FDG PET in the assessment of patients with multiple myeloma. Am J Roentgenol 2005;184:1199–204.

C Nanni , E Zamagni , M Farsad , et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging 2006;33:525–31.

I Fogelman , G Cook , O Israel , H. Wall Van DerPositron emission tomography and bone metastases [review]. Semin Nucl Med 2005;35:135–42.

DB. Kimmel Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates [review]. J Dent Res 2007;86:1022–33.

JJ Body , IJ Diel , MR Lichinitser , et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399–405.

EV Mccloskey , JA Dunn , JA Kanis , et al. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001;113:1035–43.

A Corso , E Ferretti , M. Lazzarino Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment [review]. Hematology 2005;10:215–24.

F Avcu , AU Ural , MI. Yilmaz The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane. Eur J Haematol 2005;74:496–500.

P Croucher , S Jagdev , R. Coleman The anti-tumor potential of zoledronic acid [review]. Breast 2003;12 (suppl 2):S30–6.

P Musto , A Falcone , G Sanpaolo , et al. Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk Lymphoma 2003;44:1545–8.

J Wang , NM Goodger , MA. Pogrel Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104–7.

RE. Marx Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115–17.

T Wyngaert Van Den, MT Huizing , JB. Vermorken Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol 2007;19:315–22.

S Khosla , D Burr , J Cauley , et al. American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479–91.

BM Clarke , J Boyette , E Vural , JY Suen , EJ Anaissie , BC Stack Jr. Bisphosphonates and jaw osteonecrosis: the UAMS experience. Otolaryngol Head Neck Surg 2007;136:396–400.

M Khamaisi , E Regev , N Yarom , et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007;92:1172–5.

A Corso , M Varettoni , P Zappasodi , et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007;21:1545–8.

S Lentzsch , Ehrlich LA, GD. Roodman Pathophysiology of multiple myeloma bone disease. Hematol Oncol Clin North Am 2007;21:1035–49.

DL Lacey , E Timms , HL Tan , et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165–76.

RN Pearse , EM Sordillo , S Yaccoby , et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001;98:11581–6.

E Terpos , R Szydlo , JF Apperley , et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003;102:1064–9.

O Sezer , U Heider , I Zavrski , CA KüHne , LC. Hofbauer RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101(6):2094–8.

N Giuliani , R Bataille , C Mancini , M Lazzaretti , S. Barillé Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527–33.

PI Croucher , CM Shipman , J Lippitt , et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98:3534–40.

EM Sordillo , RN. Pearse RANK-Fc: a therapeutic antagonist for RANK-L in myeloma [review]. Cancer 2003;97:802–12.

JJ Body , T Facon , RE Coleman , et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221–8.

JJ Body , P Greipp , RE Coleman , et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97(suppl 3):887–92.

SJ Choi , Y Oba , Y Gazitt , et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001;108:1833–41.

E Masih-Khan , S Trudel , C Heise , et al. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood 2006;108:3465–71.

N Giuliani , V Rizzoli , GD. Roodman Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood 2006;108:3992–6.

E Tian , F Zhan , R Walker , et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483–94.

T Oshima , M Abe , J Asano , et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005;106:3160–5.

CM Edwards , JR Edwards , ST Lwin , et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008;111:2833–42.

S Yaccoby , W Ling , F Zhan , R Walker , B Barlogie , JD Shaughnessy Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007;109:2106–11.

G Anderson , M Gries , N Kurihara , et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006;107:3098–105.

E Terpos , D Mihou , R Szydlo , et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005;19:1969–76.

P Tosi , E Zamagni , C Cellini , et al. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol 2006;76:399–404.

M Zangari , D Esseltine , F Cavallo , et al. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol 2007;82:831–3.

N Giuliani , F Morandi , S Tagliaferri , et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007;110:334–8.

E Terpos , DJ Heath , A Rahemtulla , et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalizes indices of bone remodeling in patients with relapsed multiple myeloma. Br J Haematol 2006;135:688–92.

I Zavrski , H Krebbel , B Wildemann , et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 2005;333:200–5.

H Deramond , C Depriester , P Galibert , D. Gars LePercutaneous vertebroplasty with polymethylmethacrylate. Technique, indications, and results. Radiol Clin North Am 1998;36:533–46.

A Bosch , Z. Frias Radiotherapy in the treatment of Multiple Myeloma. Int J Radiat Oncol Biol Phys 1988;15:1363–9.

JA Lust , KA. Donovan The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 1999;13:1117–25.

J Li , I Sarosi , XQ Yan , et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97:1566–71.

J Bladé , L. Rosiñol Complications of multiple myeloma. Hematol Oncol Clin North Am 2007;21:1231–46.

J Bladé , JF San Miguel , M Fontanillas , et al. Initial treatment of multiple myeloma: long-term results in 914 patients. Hematol J 2001;2:272–8.

R Lathinen , M Laakso , I Palva , et al. Randomized, placebo-controlled multicentric trial of clodronate in multiple myeloma. Lancet 1992;340:1049–52.

EV Mccloskey , IC Maclennan , MT Drayson , C Chapman , J Dunn , JA. Kanis A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998;100:317–25.

JR Berenson , A Lichtenstein , L Porter , et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488–93.

JR Berenson , BE Hillner , RA Kyle , et al. American Society of Clinical Oncology practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719–36.

RA Kyle , GC Yee , MR Somerfield , et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464–72.

A Badros , D Weikel , A Salama , et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945–52.

A Bamias , E Kastritis , C Bamia , et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580–7.

MQ Lacy , A Dispenzieri , MA Gertz , et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006;81:1047–53.

BGM Durie , M Attal , M Beksac , et al. Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc 2007; 82:516–22.

MR Mcclung , EM Lewiecki , SB Cohen , et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821–31.

R Alexanian , B Barlogie , D. Dixon Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990;150:1693–5.

J Bladé , P FernáNdez-Lama , F Bosch , et al. Renal failure in multiple myeloma. Presenting features and predictors of outcome in a series of 94 patients. Arch Intern Med 1998;158:1889–93.

J Bladé , L. RosiñOl Renal, hematologic and infectious complications in multiple myeloma. Best Pract Res Clin Haematol 2005;18:635–52.

VE Papaiakovou , A Bamias , D Gika , et al. Renal failure in multiple myeloma: incidence, correlations and prognostic significance. Leuk Lymphoma 2007;48:337–41.

R Torra , J Bladé , A Cases , et al. Patients with multiple myeloma and renal failure requiring long-term dialysis: presenting features, response to therapy and outcome in a series of 20 cases. Br J Haematol 1995;91:854–9.

M Abbate , C Zoja , G. Remuzzi How does proteinuria cause progressive renal failure? J Am Soc Nephrol 2006;17:2974–84.

SA Mezzano , M Barria , MA Droguett , et al. Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. Kidney Int 2001;60:1366–77.

R Sitia , G Palladini , G. Merlini Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 2007;92:1302–7.

GK Rangan , Y Wang , YC Tay , DC. Harris Inhibition of nuclear factor-κB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int 1999;56:118–34.

O Takase , J Hirahashi , A Takayanagi , et al. Gene transfer of truncated IkappaBalpha prevents tubulointerstitial injury. Kidney Int 2003;63:501–13.

RE Randall , WC Williamson , F Mullinax , MY Tung , WJS. Still Manifestations of systemic light-chain deposition. Am J Med 1976;60:293–9.

MV Dhodapkar , G Merlini , A. Solomon Biology and therapy of immunoglobulin deposition diseases. Hematol Oncol Clin North Am 1997;11:89–110.

SP Bernstein , DH. Humes Reversible renal insufficiency in multiple myeloma. Arch Intern Med 1982;142:2083–6.

DJ Cohen , W Sherman , EF. Osserman Acute renal failure in patients with multiple myeloma. Am J Med 1984;76:247–56.

UH Mellquist , S Lenhoff , HE Johnsen , et al. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin and dexamethasone. Cancer 2008;112:129–35.

E Kastritis , A Anagnostopoulos , M Roussou , et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high-dose dexamethasone containing regimens and impact of novel agents. Haematologica 2007;92:546–9.

JF San Miguel , JJ Lahuerta , R GarcíA-Sanz , et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000;1:28–36.

CK Lee , M Zangari , B. Barlogie Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004;33:823–28.

PG Richardson , P Sonneveld , MW Schuster , et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–98.

H Oakervee , R Popat , J. Cavenagh Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment. Leuk Lymphoma 2007;48:1910–21.

S Jagannath , B Barlogie , JR. Berenson Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005;103:1195–2000.

AA Chanan-Khan , JL Kaufman , J Metha , et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007;109:2604–6.

H Ludwig , J Drach , H Graf , JG. Meran Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007;92:1411–14.

WJ Johnson , RA Kyle , AA Pineda , PC O'Brien , KE. Holley Treatment of renal failure associated to multiple myeloma. Arch Intern Med 1990;150:863–9.

WF Clark , AK Stewart , GA Rock , et al. Plasma exchange when myeloma presents as acute renal failure. A randomized, controlled trial. Ann Intern Med 2005;143:777–84.

G Cohen , M Rudnicki , S Schmaldienst , WH. Horl Effect of dialysis on serum plasma levels of free immunoglobulin light chains in end-stage renal disease patients. Nephrol Dial Transplant 2002;17:879–83.

Bergsagel DE, AJ Bailey , GR Langley , et al. The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. N Engl J Med 1979;301:743–8.

Finnish Leukemia Group. Acute leukemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukemia group study. Eur J Haematol 2000;65:123–7.

H Ludwig , K Rai , J Bladé , et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukaemia: epoietin treatment recommendations. Hematol J 2002;3:121–30.

JD Rizzo , AE Lichtin , SH Woolf , et al. Use of epoietin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303–20.

RM Hargreaves , JR Lea , H Griffiths , et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol 1995;48:260–6.

L Snowden , J Gibson , DE. Joshua Frequency of infection in plateau-phase multiple myeloma (letter). Lancet 1994;344:262.

DG Savage , J Lindenbaum , TJ. Garret Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med 1982;96:47–50.

BR Meyers , SZ Hirschman , JA. Axelrod Current pattern of infection in multiple myeloma. Am J Med 1972;52:87–92.

BS Shaikh , RM Lombard , PC Appelbaum , MS. Bentz Changing pattern of infection in patients with multiple myeloma. Oncology 1982;39:78–82.

RT Perri , RP Hebbel , MM. Oken Influence of treatment and response status on infection in multiple myeloma. Am J Med 1981;71:935–40.

MM Oken , C Pomeroy , D. Weisdorf Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 1996;100:624–8.

SE Salmon , BA Samal , DM Hayes , et al. Role of gammaglobulin for immunoprophylaxis in multiple myeloma. N Engl J Med 1967;277:1336–40.

JB. Posner Back pain and epidural spinal cord compression. Med Clin North Am 1987;71:185–205.

E Nobile-Orazio , N Meucci , L Baldini , A Din Troia , G. Scarlato Long term prognosis of neuropathy associated with antiMAG IgM M-proteins and its relationship to immune therapies. Brain 2000;123:710–17.

C Kilidreas , A Anagnostopoulos , N Karandreas , et al. Rituximab therapy in monoclonal IgM-related neuropathies. Leuk Lymphoma 2006;47:859–64.

TD Levine , A. Pestronk IgM antibody related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999;52:1701–4.

RK Woodruff , HJC. Ireton Multiple nerve palsies as the presenting feature of meningeal myelomatosis. Cancer 1982;49:1710–12.

A Fassas , S Ward , F Muwalla , et al. Myeloma of the central nervous system: strong association with unfavourable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma 2004;45:291–300.

J Bladé , RA Kyle , PR. Greipp Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996;93:345–51.

J Bladé , RA Kyle , PR. Greipp Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch Intern Med 1996;156:1463–8.

PJ Selby , TJ Mc Elwain , AC Nandi , et al. Multiple myeloma treated with high-dose intravenous melphalan Br J Haematol 1987;66:55–62.

JA Child , GJ Morgan , FE Davies , et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–83.

A Palumbo , S Bringhen , MT Petrucci , et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50–70: results of a randomized controlled trial. Blood 2004;104:3052–7.

J Blade , L Rosinol , A Sureda , et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish Cooperative Group PETHEMA. Blood 2005;106:3755–9.

JP Fermand , S Katsahian , M Divine , et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227–33.

B Barlogie , RA Kyle , KC Anderson , et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of Phase III US Intergroup trial S9321. J Clin Oncol 2006;24:929–36.

SV Rajkumar , R Fonseca , MQ Lacy , et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 1999;23:1267–72.

J Koreth , CS Cutler , B Djulbegovic , et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007;13:183–96.

M Gertz , MQ Lacy , DJ Inwards , et al. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant 2000;26:45–50.

A Fassas , J Shaughnessy , B. Barlogie Cure of myeloma: hype or reality? Bone Marrow Transplant 2005;35:215–24.

JJ Lahuerta , J Martinez-Lopez , J Serna de la, et al. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000;109:438–46.

P Sonneveld , B Holt Van Der, CM Segeren , et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term results of the Dutch Cooperative group HOvon 24 trial. Haematologica 2007;92:928–35.

M Pineda-Roman , V Bolejack , V Arzoumian , et al. Complete response in myeloma extends survival, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 2007;136:393–9.

F Rhee van, V Bolejack , K Hollmig , et al. High serum-free light chain levels and their rapid reduction in response define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007;110:827–32.

SV Rajkumar , R Fonseca , A Dispenzieri , et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000;26:979–83.

BG Durie , J Jacobson , B Barlogie , J. Crowley Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in SWOG chemotherapy trials. J Clin Oncol 2004;22(10):1857–63.

HJK Velde van de, X Liu , G Chen , A Cakana , W Draedt , M. Bayssas Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007;92:1399–406.

RA Kyle , T Leong , S Li , et al. Complete response in multiple myeloma. Clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer 2006;106:1958–66.

PG Richardson , P Sonneveld , M Schuster , et al. Extended follow-up of a Phase III trial in relapsed multiple myeloma: final time-to-event results of the Apex trial. Blood 2007;110:3557–60.

J Blade , D Samson , D Reece , et al. Criteria for evaluating disease response and progression in patients treated with high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 1998;102:1115–23.

BG Durie , JL Harousseau , JS San Miguel , et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–73.

MA Gertz , TE Witzig , AA Pineda , et al. Monoclonal plasma cells in the blood stem-cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone marrow Transplant 1999;19:337–42.

R Lopez-Perez , R Garcia-Sanz , D Gonzalez , et al. The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Leukemia 2000;14:1493–9.

P Moreau , T Facon , M Attal , et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140mg/m2 melphalan as conditioning regimen for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 trial. Blood 2002;99:731–5.

GL Philips , BR Meisenberg , Reecede, et al. Activity of single-agent melphalan 220 to 300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone marrow Transplant 2004;33:781–7.

P Moreau , N Milpied , B Mahe , et al. Melphalan 220 mg/m2 followed by peripheral stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999;23:1003–6.

P Moreau , C Hulin , F Garban , et al. Tandem autologous stem cell transplantation in high risk-de novo multiple myeloma: final results of the prospective and randomized IFM 99–04 protocol. Blood 2006;107:397–403.

E Carreras , L Rosinol , MF Terol , et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007;13:1448–54.

M Cavo , P Tosi , E Zamagni , et al. Prospective randomized study of single compared with double autologous stem cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434–41.

E Jantunen , T Juittinen , K Penttila , et al. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>65 years) myeloma patients: comparison with younger patients treated with the same protocol. Bone marrow Transplant 2006;37:917–22.

Facont, JY Mary , C Hulin , et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomized trial. Lancet 2007;370:1209–18.

A Badros , B Barlogie , D Siegel , et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001;114:822–9.

P Tosi , E Zamagni , S Ronconi , et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and renal failure. Leukemia 2000;14:1310–3.

T Facon , H Avet-Loiseau , G Guillerm , et al. Chromosome 13 abnormalities identified by Fish analysis and serum β2 microglobulin produce powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566–71.

G Tricot , T Spencer , J Sawyer , et al. Predicting long-term (>5years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002;116;211–7.

J Shaughnessy , J Jacobson , J Sawyer , et al. Continuous absence of metaphase-defined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy ensures long-term survival in multiple myeloma treated with Total Therapy 1: interpretation in the context of global gene expression. Blood 2003;101:3849–56.

AT Fassas , T Spencer , J Sawyer , et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002;118:1041–7.

S Kumar , MQ Lacy , A Dispenzieri , et al. Single agent dexamethasone for prestem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 2004;34:485–90.

M Cavo , E Zamagni , P Tosi , et al. Superiority of thalidomide and dexamethsone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35–9.

HM Lokhorst , I Schidt-Wolf , P Sonneveld , et al. Thalidomide in induction treatment increases the very good partial remission rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008;93:124–7.

I Breitkreutz , HM Lokhorst , MS Raab , et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield Leukemia 2007;21:1294–9.

L Rosinol , A Oriol , MV Mateos , et al. Phase II Pethema trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007;25:4452–8.

M Wang , S Giralt , K Delasale , B Handy , R. Alexanian Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007;12:235–9.

MQ Lacy , MA Gertz , A Dispenzieri , et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179–84.

A Mazumder , J Kaufman , R Niesvizky , S Lonial , D Vesole , S. Jagannath Effect of lenalidomide on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008;22:1280–1.

D Cunningham , R Powles , JS Malpas , et al. A randomized trial of maintenance therapy with intron A following high dose melphalan and ABMT in myeloma. Br J Haematol 1998;102:195–202.

BT Brinker , EK Walker , T Leong , et al. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 2006;106:2171–80.

B Barlogie , G Tricot , E Anaissie , et al. Thalidomide and hematopoietic stem cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021–30.

S Singhal , J Mehta , R Desikan , et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–71.

S Jagannath , PG Richardson , P Sonneveld , et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2.3 trials. Leukemia 2007;21:151–7.

A Palumbo , S Bringhen , T Caravita , et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 2006;367:825–31.

B Barlogie , E Anaissie , F Rhee Van, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176–85.

B Barlogie , GJ Tricot , F Rhee van, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006;135:158–64.

PL. Bergsagel Individualizing therapy using molecular markers in multiple myeloma. Clin Lymphoma Myeloma 2007;(suppl 4): S170–4.

S Kumar , KC. Anderson Drug insight: thalidomide as a treatment for multiple myeloma (Review). Nat Clin Prac Oncol 2005;2:262–70.

LF Verdonck , HM Lokhorst , AW Dekker , HK Nieuwenhuis , EJ. Petersen Graft-versus-myeloma effect in two cases. Lancet 1996;347:800–1.

J Aschan , B Lonnqvist , O Ringden , G Kumlien , G. Gahrton Graft-versus-myeloma effect (Letter). Lancet 1996;348:346.

R Blanc Le, S Montminy-MéTivier , R Bélanger , et al. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant 2001;28:841–8.

J Libura , T Hoffmann , J Passweg , et al. Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 1999;24:925–7.

Burger JaBertz H, , R Kunzmann , R Mertelsmann , J. Finke Adoptive immunotherapy for relapsed multiple myeloma after allogeniec bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 1997;11:281–3.

M Salama , T Nevill , D Marcellus , et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000;26:1179–84.

J Mehta , S. Singhal Graft-versus-myeloma (Review). Bone Marrow Transplant 1998;22:835–43.

C Helg , M Starobinski , M Jeannet , B. Chapuis Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoetic stem cell transplantation (Review). Leuk Lymphoma 1998;29:301–13.

G Gahrton , H Svensson , M Cavo , et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001;113:209–16.

I Majolino , P Corradini , R Scimè , et al. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1998;22:449–55.

J Kuruvilla , JD Shepherd , HJ Sutherland , et al. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2007;13:925–31.

M Schmidt-Hieber , IW Blau , R Trenschel , et al. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2007;39:389–96.

R Storb , C Yu , B Sandmaier , et al. Mixed hematopoietic chimerism after hematopoietic stem cell allografts. Transplant Proc 1999;31:677–8.

PA Mcsweeney , D Niederwieser , JA Shizuru , et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390–400.

DG Maloney , AJ Molina , F Sahebi , et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447–54.

C-K Lee , A Badros , B Barlogie , et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003;31:73–80.

S Giralt , A Aleman , A Anagnostopoulos , et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002;30:367–73.

H Einsele , HJ Schafer , H Hebart , et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003;121:411–8.

MH Qazilbash , R Saliba , M Lima de, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006;106:1084–9.

F Elice , R Raimondi , A Tosetto , et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 2006;81:426–31.

N Kroger , R Schwerdtfeger , M Kiehl , et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100:755–60.

N Kroger , HG Sayer , R Schwerdtfeger , et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002;100:3919–24.

S Galimberti , E Benedetti , F Morabito , et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res 2005;29:961–6.

C Kahl , BE Storer , BM Sandmaier , et al. Relapse risk among patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007;110:2744–8.

KS Peggs , S Mackinnon , CD Williams , et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003;9:257–65.

M Mohty , JM Boiron , G Damaj , et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004;34:77–84.

C Crawley , M Lalancette , R Szydlo , et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;105:4532–9.

C Crawley , S Iacobelli , B Björkstrand , JF Apperley , D Niederwieser , G. Gahrton Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588–94.

F Garban , M Attal , M Michallet , et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99–03 trial) with tandem autologous stem cell transplantation (IFM99–04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474–80.

N Kroger , G Schilling , H Einsele , et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004;103:4056–61.

WI Bensinger , PJ Martin , B Storer , et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175–81.

S Giralt , W Bensinger , M Goodman , et al. 166HO-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/2 trials. Blood 2003;102:2684–91.

GA Kennedy , S Durrant , J Butler , et al. Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen. Leukemia 2005;19:879–80.

DJ Macfarlane , S Durrant , ML Bartlett , R Allison , AJ. Morton 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies. Nucl Med Commun 2002;23:1099–106.

S Giralt , W Bensinger , M Goodman , et al. Long-term follow-up of 83 patients with multiple myeloma (MM) treated on a phase I-II study of skeletal targeted radiotherapy (STR) using 166Ho-DOTMP plus melphalan with or without total body irradiation (TBI) and autologous hematopoietic stem cell transplant (AHSCT) [abstract]. Blood 2002;100 (Part 1):179a, 670.

HJ Deeg , B Storer , JT Slattery , et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002;100:1201–7.

N Kroger , B Shaw , S Iacobelli , et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005;129:631–43.

S Gerull , M Goerner , A Benner , et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005;36:963–9.

D Couriel , PA Carpenter , C Cutler , et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group report. Biol Blood Marrow Transplant 2006;12:375–96.

I Majolino , M Davoli , E Carnevalli , et al. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk Lymphoma 2007;48:759–66.

J Blade , L Rosinol , JJ Lahuerta , et al. Tandem autologous transplant versus reduced intensity conditioned allogeneic transplant (allo-RIC) as second intensification in chemosensitive patients with multiple myeloma (MM) not achieving complete remission (CR) or near-CR with a first autologous transplant. Results from a Spanish PETHEMA/GEM study [abstract]. Blood 2007;110 (Part 1):224a, 729.

M Bely , J. Makovitzky Sensitivity and specificity of Congo red staining according to Romhanyi. Comparison with Puchtler's or Bennhold's methods. Acta Histochem 2006;108:175–80.

H Puchtler , F. Sweat Congo red as a stain for fluorescence microscopy of amyloid. J Histochem Cytochem 1965;13:693–4.

W Ishii , M Matsuda , N Nakamura , et al. Phenol Congo red staining enhances the diagnostic value of abdominal fat aspiration biopsy in reactive AA amyloidosis secondary to rheumatoid arthritis. Intern Med 2003;42:400–5.

MD. Benson Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid 2005;12:75–87.

JD Sipe , AS. Cohen Review: history of the amyloid fibril. J Struct Biol 2000;130:88–98.

S Peng , J Glennert , P. Westermark Medin-amyloid: a recently characterized age-associated arterial amyloid form affects mainly arteries in the upper part of the body. Amyloid 2005;12:96–102.

C Rocken , A. Shakespeare Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002;440:111–22.

JC Hilst Van Der, A Simon , JP. Drenth Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005;5:87–98.

MB. Pepys Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Trans R Soc Lond B Biol Sci 2001;356:203–10; discussion 210–11.

PR Pokkuluri , A Solomon , DT Weiss , FJ Stevens , M. Schiffer Tertiary structure of human lambda 6 light chains. Amyloid 1999;6:165–71.

SV Rajkumar , MA Gertz , RA. Kyle Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998;82:1501–5.

MA Park , PS Mueller , RA Kyle , DR Larson , MF Plevak , MA. Gertz Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore) 2003; 82:291–8.